Arthrosamid is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection approved in Europe for the treatment of knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing osteoarthritis, which affects around one in four adults in Ireland aged over 601 (over 400,000 people)2 and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of osteoarthritis treatments on offer to meaningfully help patients – until now.
The Economic Complexity of Knee Replacement Surgery: Cost-Effectiveness and Hidden Expenses in the UK
August 20, 2025
No Comments
Knee osteoarthritis is increasingly common with an aging UK population, driving demand for knee replacement surgery. This article explores the true cost of knee replacement, breaking down direct prices, hidden expenses, and how value is measured using quality-adjusted life years (QALYs). It compares NHS and private surgery costs, access, and care quality, highlighting the financial and personal implications for patients. With rising procedures and costs, the article discusses strategies for maintaining high-quality, accessible care, including prevention, streamlined surgical pathways, and improved rehabilitation. Understanding these factors helps inform better decisions for patients and policymakers and ensures knee replacements remain both effective and affordable.
